ICD-10-CM code · FY2027
M08.261 Juvenile rheumatoid arthritis with systemic onset, right knee
BillableValid for claims as a specific diagnosis code
About M08.261
Ask EvidencePulse about juvenile arthritis
Answers from the published evidence, with every study linked. The question goes into the box; nothing is sent until you press Ask.
Coding notes for M08.261
No notes of its own; the notes below apply from the codes above it.
Also applies, from M08.2 Juvenile rheumatoid arthritis with systemic onset
Excludes1 Not coded here: never report these together with this code (use the code given instead).
- adult-onset Still's disease (M06.1-)
Also applies, from M08 Juvenile arthritis
Excludes1 Not coded here: never report these together with this code (use the code given instead).
Code also Another code may be needed as well; the order depends on the encounter.
Chapter 13 notes (apply to every code in it)
Note
- Use an external cause code following the code for the musculoskeletal condition, if applicable, to identify the cause of the musculoskeletal condition
Excludes2 Not part of this condition, but a patient can have both: report both codes when both apply.
- arthropathic psoriasis (L40.5-)
- certain conditions originating in the perinatal period (P04-P96)
- certain infectious and parasitic diseases (A00-B99)
- compartment syndrome (traumatic) (T79.A-)
- complications of pregnancy, childbirth and the puerperium (O00-O9A)
- congenital malformations, deformations, and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
Related codes in M08.26
Latest research on juvenile arthritis
- 2 Minute Medicine Rewind
- Tofacitinib may improve patient-reported outcomes in juvenile idiopathic arthritis
- Johnson & Johnson’s Tremfya seeks to expand FDA approval for pediatric indications to treat juvenile psoriatic arthritis
- #VisualAbstract: Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis
- Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis
Landmark trials from 2MM Classics
2MM+
Read the research behind every diagnosis
2MM+ gives you every study summary in full, Classics downloads of the landmark trials, EvidencePulse and HypeCheck, and ad-free reading.
See 2MM+ plans